Table 2.

Safety assessment.

	Control group				KRT group
	Patient #1	Patient #1	Patient #2	Patient #3	Patient #4
Adverse event	Dry skin	Erythema on right cheek	Cold	Xerotic eczema	Exacerbated rash
Severity	Not serious	Not serious	Not serious	Not serious	Not serious
Speculated drug	Adapalene	Adapalene	-	Adapalene	Keigairengyoto
Outcome	Improved	Improved	Recovered	Recovered	Recovered
Observation time†	1 week	1 week	3 weeks + 5 days	3 weeks + 1 day	4 days
Belonging to PPS	Yes	Yes	Yes	Yes	No

Patients were randomized into the conventional treatment group (control group) or the conventional treatment group with Keigairengyoto (KRT group), and they were treated for 12 weeks. Adverse events of local and systemic symptoms were collected throughout the study period.

^†Observation time shows the duration from the start of treatment in the present study to finding an adverse event. PPS, per protocol set.